Science, Data, and Facts Should Unite Decision-Making, Says PMI CEO in Speech at Concordia Summit
24.9.2020 22:20:00 EEST | Business Wire | Press release
André Calantzopoulos, CEO of Philip Morris International (PMI) (NYSE: PM), today delivered high-level remarks at the 2020 Concordia Annual Summit. Calantzopoulos discussed the impact that uncertainty, polarization, hyperpartisanship, and ideology are having on international efforts to overcome pressing global issues. He called for science to be protected from politicization and highlighted the importance of developing open dialogues based on factual scientific objectivity. Calantzopoulos shared PMI’s belief that with the right regulatory encouragement and support from civil society, cigarette sales can end within 10 to 15 years in many countries.
The Concordia Annual Summit, which coincides with the United Nations General Assembly (UNGA) meeting, convenes the world’s most prominent business, government, and nonprofit leaders to foster dialogue and enable effective partnerships for positive social impact.
Excerpts of the remarks by André Calantzopoulos follow:
“Reflecting on the state of our world today and the challenges ahead, four words come to mind: Uncertainty. Polarization. Hyperpartisanship. Ideology.
“These words are not new, but with the COVID crisis, they have gained prominence, moving beyond traditionally contentious sectors such as ours and into the mainstream.
“The lockdowns that sent us into our homes earlier this year, the continued uncertainty we all feel, and the immense socioeconomic pressure caused by the pandemic have increased tensions and reinforced the polarization of both private views and the public discourse.
“And while these past months have revealed how much can be accomplished when people work together, the tendency of individuals to put their self-centered impulses ahead of community wellness remains on display.
“Divisiveness—a binary choosing of sides—not only hinders progress but threatens to thwart it.
“Maybe there is no silver-bullet solution—but to focus on respect for and adherence to facts, dialogue, inclusion, and science could help immensely. It is not enough, however, to simply say ‘follow the facts and the science’ and expect progress to unfold. COVID-19 is just the latest example that proves a tragic truth: Science can be, and is being, weaponized to suit narrow agendas. Science and facts are being held hostage—and distorted—by politics, and people are suffering as a result.
“As a society, we are experiencing a confluence of global existential threats. These threats require collective, multilateral discussions and cooperation—and that can only be achieved through a commitment to open dialogue.
“Absent a commitment to factual scientific objectivity—free of agenda-driven politics—we risk the very real and terrifying prospect of vaccine nationalism, an inability to tackle climate change at scale, and a narrowed chance of delivering solutions that create a fairer and more equitable world.
“In a global world, in a global economic and human system, whether we like it or not, there is no solution in isolation. Individual governments or companies alone cannot bring the necessary change. If we want to make the United Nations Sustainable Development Goals a reality, if we want to protect our populations from the pandemic, including implementing a viable vaccine, we must work together. And most important, we must involve the 7.8 billion people on this planet. How do we do this? We tell them what the real problems are—offering the full facts; we propose solutions they can adopt or adapt; and we incentivize them to act in accordance with this new knowledge. We won’t succeed by keeping them in the dark, by confusing them, or by misleading them.
“Being at the helm of the largest multinational tobacco company as it transforms to deliver a smoke-free future, I experience firsthand how detrimental polarization is to making real progress—in this case, progress in eradicating smoking. And, as a reminder, this concerns more than 1 billion men and women who smoke around the world.
“Today, science-based, innovative products that do not involve combustion offer a better alternative for those men and women who would otherwise continue to smoke. To be clear: These products are not risk-free. And the best choice is never to start smoking or to quit tobacco and nicotine altogether. But for those adults who would otherwise continue to smoke, scientifically validated smoke-free products are a much better choice than cigarettes.
“A future in which cigarettes are obsolete is within reach. In fact, with the right regulatory encouragement and support from civil society, we believe cigarette sales can end within 10 to 15 years in many countries. Yes, that’s right: an end to cigarettes within 10 to 15 years in many countries.
“Unfortunately, political agendas and ideology are slowing progress and keeping millions of people uninformed. Rather than holding an evidence-based conversation on how best to regulate these innovative products to help adult smokers leave cigarettes behind, we are often faced with an ideologically driven resistance from some public health organizations and some NGOs. These organizations allow disinformation to appear as legitimate science. They put dogma before data, and they expend more energy on attacking a company than on helping the human beings who should be at the center of the debate.
“Poorly executed scientific studies, skewed results shaped by bias, and misleading media headlines are now the norm.
“What is the result? Many adults who smoke are confused about these better alternatives and so continue to use cigarettes—the most harmful way of consuming nicotine. This is inexcusable. We must ask: Who will take responsibility for denying these adults access to and accurate information about science-backed innovations? Who will be held responsible for the real-world consequences of dogmatic thinking?
“The issues created by uncertainty, polarization, hyperpartisanship, and ideology are not unique to the tobacco sector. From climate change to food security, we need fact-based conversations and a collaborative, multinational, multi-stakeholder approach to deliver real change. The public has a right to decision-making and information based in science. We cannot allow politically driven, well-funded individuals to prevent the world’s citizens from learning about and accessing smart solutions. Whether we are talking about vaccines, carbon emissions, or tobacco harm reduction, we need science, not rhetoric, to inform policies and regulations.
“Science unites. It has the power to open borders and minds and bring progress. It can propel innovation.
“For Philip Morris International, science has changed our company and is transforming our industry. I am proud to come before you today to say that, already, more than 11.2 million people have switched to our main smoke-free product and stopped smoking. Many more have switched to other smoke-free alternatives that are better than continued smoking. This is a profound public health achievement.
“Governments across the world—in Greece, New Zealand, the United Kingdom, and beyond—are beginning to validate the role better alternatives to continued smoking can play. Earlier this year, the U.S. Food and Drug Administration authorized our electronically heated tobacco system, IQOS, as a modified risk tobacco product. In doing so, the agency found that an exposure modification order is ‘appropriate to promote the public health.’
“But a smoke-free future is not yet guaranteed. Ridding the world of cigarettes will require adherence to science, objectivity, collaboration, and a commitment to accelerate information to the people most directly concerned.
“Many years ago, our industry was challenged to create a better alternative to cigarettes. PMI answered that call. We have transformed our entire company to devise and produce scientifically substantiated better products with the aim of delivering a smoke-free future. Science, data, and fact have led us here.
“People who smoke are responding to our efforts. With the right regulations and related information, they could switch out of cigarettes much faster. Let’s put these people—not politics—at the center of policymaking.
“Science secures progress. It secures solutions. It brings hope at a time when global challenges are so great they threaten to overwhelm. We should not allow science to be politicized and polarized.”
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the United States. In addition, PMI ships a version of its IQOS Platform 1 device and its consumables authorized by the U.S. Food and Drug Administration to Altria Group, Inc. for sale in the U.S. under license. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free IQOS product portfolio includes heat-not-burn and nicotine-containing vapor products. As of June 30, 2020, PMI estimates that approximately 11.2 million adult smokers around the world have already stopped smoking and switched to PMI’s heat-not-burn product, available for sale in 57 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com.
# # #
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200924005853/en/
Contact information
Philip Morris International
David Fraser
T. +41 (0)79 843 8603
E. david.fraser@pmi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
